CM 4620

Drug Profile

CM 4620

Alternative Names: CM-4620

Latest Information Update: 23 Jan 2017

Price : $50

At a glance

  • Originator CalciMedica
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Immunosuppressants; ORAI1 protein inhibitors; STIM1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatitis

Most Recent Events

  • 06 Jan 2017 Phase-I clinical trials in Pancreatitis (In volunteers) in USA (Parenteral)
  • 14 Nov 2016 CalciMedica plans phase II trial of CM 4620 for Pancreatitis
  • 11 Nov 2016 Preclinical trials in Pancreatitis in USA (Parenteral) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top